Akarkara for Health & Longevity - Quick Reference Sheet

Akarkara for Health & Longevity

Created on 09/22/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Akarkara is the dried root of a Mediterranean daisy, sold as a dietary supplement for male sexual vigor and long used against toothache. Oral contact produces tingling, numbness, and heavy salivation within seconds. Almost everything else rests on animal and laboratory work: no human study has tested the root alone for any internal effect. Liver and kidney changes appear in animals at amounts not far above those sold. (Full Review)

Protocol

Traditional whole-root approach
250 mg – 1 g
Root powder daily, taken with warm milk or honey, as codified in Ayurvedic practice — the form with the longest use record
Timing within the day
With a fat-containing meal
Alkylamides are fat-soluble; morning dosing is preferable while sedation sensitivity is unknown
Half-life and dose splitting
Two doses daily
A half-life near two hours argues for splitting the daily amount to avoid a single high peak concentration
Time to effect
Systemic Effects
25–56 days
Every systemic effect reported in animals required this long; anything shorter than a month cannot be judged either way
Facial Skin Measures
12 weeks
Duration over which a gel containing 10% root extract improved measured skin parameters
Oral Tingling & Salivation
Immediate
Onset within seconds to minutes of oral contact, subsiding over roughly 15–30 minutes

Benefits

Contraindications
  • Pregnant or breastfeeding women
  • Known daisy-family (Asteraceae) contact allergy (ragweed, chamomile, arnica, feverfew)
  • Active liver disease or transaminases above twice the upper limit of normal
  • Autoimmune disease or immunosuppressive therapy
  • Hormone-sensitive prostate disease (active prostate cancer, untreated benign prostatic hyperplasia above moderate symptom score)
  • Children and adolescents under 18
  • Epilepsy, where it would replace prescribed antiepileptic therapy
Key Interactions
  • Sedatives and central depressants (diazepam, zolpidem, oxycodone, alcohol)
  • Opioid analgesics (morphine, tramadol, codeine)
  • Antiepileptic drugs (valproate, levetiracetam, carbamazepine)
  • Drugs metabolized by CYP3A4 (simvastatin, amlodipine, tacrolimus)
  • Over-the-counter analgesics and anti-inflammatories (ibuprofen, naproxen, aspirin)
  • Over-the-counter antihistamines and sleep aids (diphenhydramine, doxylamine)
  • Androgenic and pro-fertility supplements (Tribulus terrestris, Mucuna pruriens, Eurycoma longifolia, ashwagandha)
  • Immunostimulant supplements (echinacea, astragalus, beta-glucans)
  • Topical or dental anaesthetics (benzocaine, lidocaine gels)
  • Dental and oral procedures

Risk & Side Effects

  • Medium: Oral tingling, numbness, and hypersalivation
  • Low: Dose-dependent liver and kidney injury; sedation and central nervous system depression; allergic reactions in daisy-family–sensitive people; cytotoxicity of concentrated extract to cultured cells
  • Speculative: Stimulation of androgen-sensitive tissue; immune activation in autoimmune disease; adverse effects in pregnancy

Monitoring

Marker Target Why
Total testosterone (men) 600–900 ng/dL Headroom for the main claimed effect, and the direction of any change
Luteinizing hormone 2–6 IU/L Distinguishes a pituitary-driven rise, the mechanism animal data describe, from a direct testicular one
Alanine aminotransferase (ALT) Under 25 U/L in men, under 20 U/L in women The single clearest safety signal in the animal data
Aspartate aminotransferase (AST) Under 25 U/L Rose earliest and at the lowest dose in the animal toxicity study
Estimated glomerular filtration rate (eGFR) Above 90 mL/min/1.73 m² Kidney tubular changes appeared alongside liver findings at high animal doses
Prostate-specific antigen (PSA) Under 1.0 ng/mL under age 50, under 2.5 ng/mL thereafter Covers the speculative androgen-sensitive-tissue concern
High-sensitivity C-reactive protein (hs-CRP) Under 0.5 mg/L Tracks the anti-inflammatory direction the animal data suggest
Semen analysis (concentration and total motility) No established target for this herb — track change from the individual's own baseline The endpoint with the most animal support

Cadence: Baseline panel before starting; liver panel repeats at eight weeks; hormones and, where relevant, semen analysis at twelve weeks; every six to twelve months while use continues

Qualitative Assessment

  • Libido and spontaneous sexual interest, rated weekly rather than recalled at the end of a course
  • Oral tingling intensity and duration, which indicates whether the material is pharmacologically active at all
  • Daytime drowsiness or mental dulling, the earliest sign of the sedation seen in animals
  • Joint or muscle pain levels, where the anti-inflammatory signal would first show
  • Digestive comfort, since the root's fermentable fibre content can be mistaken for a drug effect